The Benzodiazepines: Kinetic-Dynamic Relationships

  • David J. Greenblatt


The primary pharmacologic actions of the benzodiazepine derivatives include: reduction of anxiety, induction of sleep, and anti-seizure effects. Establishing kinetic-dynamic relationships for this class of drugs is a particular challenge, since reliable quantitation of these primary pharmacologic actions is difficult to achieve. This chapter reviews methodologic issues in studying the pharmacokinetic profile and the pharmacodynamic properties of benzodiazepine derivatives, and methods for quantitative linkage of plasma concentrations with clinical effects.


Panic Disorder Digit Symbol Substitution Test Intravenous Diazepam Impaired Psychomotor Performance Active Drug Therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ballenger, J. C., G. D. Burrows, R. L. DuPont, I. M. Lesser, R. Noyes, Jr., J. C. Pecknold, A. Rifkin, and R. P. Swinson (1988). Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch. Gen. Psychiatry, 45, 413–422.PubMedCrossRefGoogle Scholar
  2. Barnhill, J. G., D. J. Greenblatt, L. G. Miller, A. Gaver, J. S. Harmatz and R. I. Shader (1990). Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J. Pharmacol. Exp. Ther., 253 1153–1161.PubMedGoogle Scholar
  3. Ghoneim, M. M., and S. P. Mewaldt (1990). Benzodiazepines and human memory: a review. Anesthesiology, 72 926–938.PubMedCrossRefGoogle Scholar
  4. Greenblatt, D. J., and V. H. Sethy (1990). Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psycho-pharmacology, 102 373–378.CrossRefGoogle Scholar
  5. Greenblatt, D. J., and R. I. Shader (1987). Pharmacokinetics of antianxiety agents. In H. Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York. pp. 1377–1386.Google Scholar
  6. Greenblatt, D. J., R. I. Shader, and D. R. Abernethy (1983). Current status of benzodiazepines. N. Engl. J. Med., 309 354–358, 410–416.Google Scholar
  7. Greenblatt, D. J., B. L. Ehrenberg, J. Gunderman, A. Locniskar, J. M. Scavone, J. S. Harmatz, and R. I. Shader (1989a). Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin. Pharmacol. Ther., 45 356–365.CrossRefGoogle Scholar
  8. Greenblatt, D. J., B. L. Ehrenberg, J. Gunderman, J. M. Scavone, N. T. Tai, J. S. Harmatz, and R. I. Shader (1989b). Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J. Pharmacol. Exp. Ther., 250 134–140.Google Scholar
  9. Greenblatt, D. J., J. S. Harmatz, and R. I. Shader (1991a). Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Parts I and II). Clin. Pharmacokinet. 21, 165–177, 262–273.Google Scholar
  10. Greenblatt, D.J., J. S. Harmatz, L. Shapiro, N. Engelhardt, T. A. Gouthro and R. I. Shader (1991b). Sensitivity to triazolam in the elderly. N. Engl. J. Med. 324, 1691–1698.CrossRefGoogle Scholar
  11. Hommer, D. W., V. Matsuo, O. Wolkowitz, G. Chrousos, D. J. Greenblatt, H. Weingartner, and S. M. Paul (1986). Benzodiazepine sensitivity in normal human subjects. Arch. Gen. Psych.. 43 542–551.CrossRefGoogle Scholar
  12. Johnson, L. C., and D. A. Chernik (1982). Sedative-hypnotics and human performance. Psychopharmacology, 76 101–113.PubMedCrossRefGoogle Scholar
  13. Koelega, H. S. (1989). Benzodiazepines and vigilance performance: a review. Psychopharmacology, 98 145–156.PubMedCrossRefGoogle Scholar
  14. Lapierre, K. A., D. J. Greenblatt, J. E. Goddard, J. S. Harmatz, and R. I. Shader (1990). The neuropsychiatric effects of asparatame in normal volunteers. J. Clin. Pharmacol. 30, 454–460.PubMedCrossRefGoogle Scholar
  15. Miller, L. G., D. J. Greenblatt, J. G. Barnhill, and R. I. Shader (1988). Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function. J. Pharmacol. Exp. Ther., 246 170–176.PubMedGoogle Scholar
  16. Miller, L. G., D. J. Greenblatt, S. M. Paul, and R. I. Shader (1987). Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J. Pharmacol. Exp. Ther., 240 516–522.Google Scholar
  17. Roy-Byrne, P. P., D. S. Cowley, D. J. Greenblatt, and R. I. Shader (1990). Reduced benzodiazepine sensitivity in panic disorder. Arch. Gen. Psychiatry. 47 534–540.PubMedCrossRefGoogle Scholar
  18. Smith, R. B., and P. D. Kroboth (1987). Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93,105–112.Google Scholar
  19. Smith, R. B., P. D. Kroboth, J. T. Vanderlugt, J. P. Phillips, and R. P. Juhl (1984). Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology, 48 452–456.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • David J. Greenblatt
    • 1
  1. 1.Division of Clinical Pharmacology Department of Pharmacology and Experimental TherapeuticsTufts University School of Medicine and New England Medical Center HospitalBostonUSA

Personalised recommendations